Biotech pain con­tin­ues as Ver­sant, MPM gene ther­a­py start­up calls it quits

A gene ther­a­py start­up backed by two key bio­phar­mas and two pre­mier biotech VC firms has ceased op­er­a­tions.

Cal­i­for­nia biotech Co­da Bio­ther­a­peu­tics shut down re­cent­ly, in­vestors Ver­sant Ven­tures and MPM Cap­i­tal con­firmed to End­points News Tues­day night, de­clin­ing to pro­vide fur­ther de­tails. The up­start had pre­sent­ed pre­clin­i­cal da­ta on its pro­gram for fo­cal epilep­sy last sum­mer but had not pro­vid­ed an up­date since then. MPM re­moved Co­da from its port­fo­lio page in re­cent weeks, per in­ter­net archives, and the biotech’s LinkedIn page has been wiped.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER